The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti(Vita-Salute San Raffaele University), Marco Moschini(Vita-Salute San Raffaele University), Évanguelos Xylinas(NewYork–Presbyterian Hospital), David D‘Andrea(Medical University of Vienna), Ekaterina Laukhtina(Comprehensive Cancer Center Vienna), Paolo Gontero(Fondazione Ricerca Molinette), Aleksander Ślusarczyk(Medical University of Warsaw), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Keiichiro Mori(Jikei University School of Medicine), Benjamin Pradère, Simone Albisinni(University of Rome Tor Vergata), Mario de Angelis(IRCCS Ospedale San Raffaele), José Daniel Subiela(Universidad de Alcalá), Renate Pichler(Innsbruck Medical University), Shahrokh F. Shariat(Universitätszahnklinik Wien), Andrea Necchi(Vita-Salute San Raffaele University), Piotr Radziszewski(Medical University of Warsaw), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Morgan Rouprêt(Sorbonne Université), Francesco Soria, Laura S. Mertens(Oncode Institute), Francesco Montorsi(Vita-Salute San Raffaele University), Wojciech Krajewski(Wroclaw Medical University)
Cited by 29
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k